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Reply
As Dr. Cao and colleagues point out, our recently published
cost-effectiveness analysis, based on patient-level data from the
PARTNER (Placement of Aortic Transcatheter Valves Trial) (1)
has some important limitations. Our analysis used a 12-month
timeframe. From a health economic perspective, this analytic
timeframe is similar to an analysis that assumes that long-term
outcomes between study groups will be comparable. Although
there is presently no empirical evidence suggesting otherwise, this
remains an unproven assumption, which we explicitly noted in the
manuscript.
Also correctly noted was the fact that hospital length of stay
(LOS) was shorter after transcatheter aortic valve replacement
(TAVR) than after surgical aortic valve replacement (AVR),
and the savings associated with reduced LOS play a key role in
offsetting the higher acquisition cost of a transcatheter valve.
The LOS following surgical AVR in the PARTNER trial was
indeed long—about 6 days longer than average LOS for AVR
for all U.S. patients (2). We believe the long LOS after surgical
AVR in the PARTNER trial was primarily related to the
unique risk profile of the patient population, who represent the
highest 5% to 8% risk of patients operated on for aortic stenosis
in the United States. Based on recent publications, it is clear
that “high-risk” patients who currently undergo TAVR in other
countries tend to be lower risk than those who were studied in
the PARTNER A trial. For example, the SOURCE-XT registry
f 2,700 consecutive patients undergoing TAVR in 17 countries
nrolled patients with a mean Society of Thoracic Surgeons (STS)
ortality risk of 8.5% (4) whereas the PARTNER trial population
ad a mean STS mortality risk of 11.8% (3). Moreover, as we
oted in our discussion, even for similar patients, clinical results
nd resource utilization patterns may differ across healthcare
ystems. We agree that country-specific analyses are needed, but
e are concerned about conclusions reached by comparing non-
andomized groups (5). In the absence of randomization, careful
isk adjustment is required to reach balanced conclusions.
Finally, it is not correct to state that our analysis ignored or
eglected complications associated with TAVR. For the TAVR
nd AVR groups in the trial, we measured costs for index and
ollow-up hospitalizations primarily by collecting and analyzing
ospital bills from the enrolling centers. Thus, while we have not
et reported the excess costs associated with specific complications,
hose costs were incorporated into analysis through the 12-month
imeframe of the study.
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Diagnosis of Heart Failure With
Preserved Ejection Fraction
Still a Challenge
Campbell et al. (1) addressed a key issue of heart failure with
preserved ejection fraction (HFPEF). Does it really exist? They
concluded that it does, because of the differences in outcomes,
comorbidities, and biomarkers between hypertensive and HF-
PEF patients in clinical trials. When these studies were carried
out, the performance of diagnostic criteria for HFPEF was
poor. These criteria were omitted from the latest guidelines of
the European Society of Cardiology (ESC). Diagnosis of
HFPEF relies more on left ventricular mass and left atrial size
(2) than on the signs of diastolic dysfunction. The study fails to
discuss whether the majority of patients included in clinical
trials actually had HFPEF. Our view is that inclusion of
patients with a clinical picture similar to HF—termed the
EXIT (EXercise InTolerance) syndrome (3)—may account for
the observed differences. Ingle et al. (4) showed that a propor-
tion of patients diagnosed with HFPEF actually had another
entity, clinically similar to HF, with lower B-type natriuretic
peptide concentrations and a better prognosis. Among exercise-
intolerant patients, age, comorbidities, atrial fibrillation, obe-
sity, deconditioning, and unexpected degrees of renal dysfunc-
tion might play an important role. This might explain why
sensitive markers of glomerular filtration rate, such as cystatin
C, perform so well in patients with HFPEF (5). Almeida et al.
(6) showed that patients with acutely decompensated HFPEF,
who fulfilled the ESC diagnostic criteria had a worse prognosis,
comparable to HF and a reduced ejection fraction (HFREF).
These data suggested an exercise-intolerance syndrome, similar
to HFPEF, with a better prognosis—a factor that could have
distorted the results of HFPEF clinical trials and might account
for the differences in prognosis between HFPEF and HFREF.
We consider HFPEF to be a reality, although doubts as to its
clinical profile and diagnostic criteria still persist beyond the
conclusions of the study by Campbell et al. (1). The challenge
is to identify them without the need for complex assessments.
